Evidence map›Paper›PMID 24942588›Full record

ArticleJournal of virology2014

Murine cytomegalovirus virion-associated protein M45 mediates rapid NF-κB activation after infection.

Eva Krause, Miranda de Graaf, Patricia M Fliss, Lars Dölken, Wolfram Brune

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 34 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Programmed Necrosis in Host Defense.Current topics in microbiology and immunology · 2023
    Article
  11. Article
  12. Article
  13. Viral Induced Protein Aggregation: A Mechanism of Immune Evasion.International journal of molecular sciences · 2021
    Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Eva KrauseHeinrich Pette Institute, Leibniz Institute for Experimental Virology, Hamburg, Germany.
Miranda de GraafDepartment of Medicine, University of Cambridge, Cambridge, United Kingdom.
Patricia M FlissHeinrich Pette Institute, Leibniz Institute for Experimental Virology, Hamburg, Germany.
Lars DölkenDepartment of Medicine, University of Cambridge, Cambridge, United Kingdom.
Wolfram BruneHeinrich Pette Institute, Leibniz Institute for Experimental Virology, Hamburg, Germany wolfram.brune@hpi.uni-hamburg.de.
Leibniz Institute of Virology (LIV) · DEUniversity of Cambridge · GB

Funding

Medical Research Council G1002523
6 · The paper itself

Abstract

unlabelledMurine cytomegalovirus (MCMV) rapidly induces activation of nuclear factor κB (NF-κB) upon infection of host cells. After a transient phase of activation, the MCMV M45 protein blocks all canonical NF-κB-activating pathways by inducing the degradation of the gamma subunit of the inhibitor of κB kinase complex (IKKγ; commonly referred to as the NF-κB essential modulator [NEMO]). Here we show that the viral M45 protein also mediates rapid NF-κB activation immediately after infection. MCMV mutants lacking M45 or expressing C-terminally truncated M45 proteins induced neither NF-κB activation nor transcription of NF-κB-dependent genes within the first 3 h of infection. Rapid NF-κB activation was absent in MCMV-infected NEMO-deficient fibroblasts, indicating that activation occurs at or upstream of the IKK complex. NF-κB activation was strongly reduced in murine fibroblasts lacking receptor-interacting protein 1 (RIP1), a known M45-interacting protein, but was restored upon complementation with murine RIP1. However, the ability of M45 to interact with RIP1 and NEMO was not sufficient to induce NF-κB activation upon infection. In addition, incorporation of the M45 protein into virions was required. This was dependent on a C-terminal region of M45, which is not required for interaction with RIP1 and NEMO. We propose a model in which M45 delivered by viral particles activates NF-κB, presumably involving an interaction with RIP1 and NEMO. Later in infection, expression of M45 induces the degradation of NEMO and the shutdown of canonical NF-κB activation. IMPORTANCE: Transcription factor NF-κB is an important regulator of innate and adaptive immunity. Its activation can be beneficial or detrimental for viral pathogens. Therefore, many viruses interfere with NF-κB signaling by stimulating or inhibiting the activation of this transcription factor. Cytomegaloviruses, opportunistic pathogens that cause lifelong infections in their hosts, activate NF-κB rapidly and transiently upon infection but block NF-κB signaling soon thereafter. Here we report the surprising finding that the murine cytomegalovirus protein M45, a component of viral particles, plays a dual role in NF-κB signaling. It not only blocks NF-κB signaling later in infection but also triggers the rapid activation of NF-κB immediately following virus entry into host cells. Both activation and inhibition involve M45 interaction with the cellular signaling mediators RIP1 and NEMO. Similar dual functions in NF-κB signaling are likely to be found in other viral proteins.

Indexed as

AnimalsCells, CulturedGenetic Complementation TestGTPase-Activating ProteinsIntracellular Signaling Peptides and ProteinsMiceMice, KnockoutMuromegalovirusNF-kappa BProtein Interaction MappingRibonucleotide ReductasesViral ProteinsGTPase-Activating ProteinsIntracellular Signaling Peptides and Proteinsm45 protein, Mouse cytomegalovirus 1NEMO protein, mouseNF-kappa BRalbp1 protein, mouseRibonucleotide ReductasesViral Proteins

Identifiers

PMID24942588
PMCPMC4136316
OpenAlexW2111633153

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.